Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: David L. Hachey who wrote (15858)	2/25/1998 12:30:00 PM
From: Henry Niman	Respond to of 32384

Dave, I think that all of Targretin's and Panretin's trials deliver the drugs orally (other than the gel formulations). I have not seen any data on IV or other routes (other than in animals). I think that the bioavailability may be better for some of the second generation rexinoids and would expect LGND to do trials on those drugs rather than trials on IV injections for Targretin or any other drug identified through their two core technologies. One of LGND's stated goals for their IR and STAT technologies is to develop drugs that can be taken orally.